Blood pressure-lowering effects of statins: Who benefits?

Journal of Hypertension

Volumn 27, Issue 7, 2009, Pages 1478-1484

  Bautista, Leonelo E ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antihypertensive agents; Blood pressure; Hydroxymethylglutaryl CoA reductase inhibitors; Hypertension; National Health and Nutrition Examination Surveys

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 67649800348     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832b1e78     Document Type: Article

References (44)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344:1383-1389.
2. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet1996; 348:1339-1342.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
5. Farmer JA, Gotto AM Jr. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 2003; 92:3i-9i.
6. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711-1718.
7. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004; 109:II42-II48.
8. Chopra V, Choksi PU, Cavusoglu E. Beyond lipid lowering: the antihypertensive role of statins. Cardiovasc Drugs Ther 2007; 21:161-169.
9. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipidindependent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149:473.e1-473. e10.
10. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104:376-379.
11. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20:61-69.
12. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22:300-305.
13. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933-1935.
14. Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on highsensitive C-reactive protein levels. Atherosclerosis 2003; 169:155-158.
15. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100:2131-2134.
16. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003; 25:1107-1122.
17. O'Callaghan CJ, Krum H, Conway EL, et al. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press 1994; 3:404-406.
18. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34:1281-1286.
19. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39:1020-1025.
20. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure: a meta-analysis of randomized, controlled trials. Hypertension 2007; 49:792-798.
21. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168:721-727.
22. National Center for Health Statistics Centers for Disease Control and Prevention. Analytic and reporting guidelines. The National Health and Nutrition Examination Survey (NHANES). National Center for Health Statistics Centers for Disease Control and Prevention, 2006.
23. Perloff D, Grim C, Flack J, et al. Human blood pressure determination by sphygmomanometry. Circulation 1993; 88:2460-2470.
24. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18:681- 694.
25. Rubin D. Multiple imputation for nonresponse in surveys. New York, NY: Wiley.
26. Austin PC, Tu JV, Daly PA, Alter DA. The use of quantile regression in healthcare research: a case study examining gender differences in the timeliness of thrombolytic therapy. Stat Med 2005; 24:791-816.
27. Austin PC, Schull MJ. Quantile regression: a statistical tool for out-ofhospital research. Acad Emerg Med 2003; 10:789-797.
28. Korn EL, Graubard BI. Analyses using multiple surveys. In Korn EL, Graubard BI, editors. Analysis of health surveys. New York: John Wiley & Sons, Inc., 159-91.
29. Rogers WH. Quantile regression standard errors. Stata Technical Bulletin Reprints 1992; 2:133-137.
30. Gould W. Quantile regression with boostrapped standard errors. Stata Technical Bulletin 1992; 9:19-21.
31. Toikka JO, Ahotupa M, Viikari JS, et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDLoxidation in healthy young men. Atherosclerosis 1999; 147:133-138.
32. Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. Rev Cardiovasc Med 2001; 2:29-40.
33. Mangat S, Agarwal S, Rosendorff C. Do statins lower blood pressure? J Cardiovasc Pharmacol Ther 2007; 12:112-123.
34. Sinha AK, Mehta JL. Modulation of atherosclerosis, blood pressure and arterial elasticity by statins. Adv Cardiol 2007; 44:315-330.
35. Wierzbicki AS. Lipid lowering: another method of reducing blood pressure? J Hum Hypertens 2002; 16:753-760.
36. Tomochika Y, Okuda F, Tanaka N, et al. Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol1996; 16:955-962.
37. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterollowering actions. J Am Coll Cardiol 1999; 33:234-241.
38. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001; 104:1767-1772.
39. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003; 170:315-323.
40. Okosun IS, Tedders SH, Choi S, Dever GE. Abdominal adiposity values associated with established body mass indexes in white, black and hispanic Americans. A study from the Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 2000; 24:1279-1285.
41. Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35:1021- 1024.
42. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055-1076.
43. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155:701-709.
44. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-1315.